Thomas, Ranjeeta http://orcid.org/0000-0002-0947-4574
Skovdal, Morten
Galizzi, Matteo M.
Schaefer, Robin
Moorhouse, Louisa
Nyamukapa, Constance
Maswera, Rufurwokuda
Mandizvidza, Phyllis
Hallett, Timothy B.
Gregson, Simon
Funding for this research was provided by:
National Institutes of Mental Health (R01MH114562-01)
Bill and Melinda Gates Foundation (OPP1161471)
MRC Centre for Global Infectious Disease Analysis funding from the UK Medical Research Council and Department for International Development (MR/R015600/1)
Article History
Received: 28 May 2019
Accepted: 6 January 2020
First Online: 23 January 2020
Ethics approval and consent to participate
: As described above, this study has been approved from the MRC of Zimbabwe (reference number: MRCZ/A/2243), the Biomedical Research and Training Institute, Zimbabwe, Institutional Review Board (reference number: AP140/2017) and the Imperial College London Research Ethics Committee (reference number: 17IC4160). Each participant will provide written informed consent prior to the initiation of baseline assessments or the intervention.
: Not applicable.
: SG declares shares in GlaxoSmithKline and AstraZeneca. TBH declares grants outside the subject area from UNAIDS (Joint United Nations Programme on HIV and AIDS), the World Health Organization, the BMGF, and the MRC. RT declares grants outside the subject area from the European and Developing Countries Clinical Trials Partnership. The other authors declare that they have no competing interests.